Queensland’s Department of Transport and Main Roads (TMR) has begun a review of the state’s drug-driving laws – but it’s not due to be completed until the end of 2024.

Responding to an enquiry on behalf of TMR minister Mark Bailey, general manager (land transport safety and regulation) Andrew Mahon said the review will examine best practice approaches across the world as well as the latest research. 

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Join the Conversation

1 Comment

  1. Great to see that at least they are willing to look at it. The one thing that is totally missing in Mahon’s logic is the link with benzos, opiates and anticonvulsants, where his statement: “XXX can also interact with other medications, impairing the metabolism of other drugs or causing cumulative effects such as sedation. There are also differences in the impairing effects of XXX based on length of use, quantity and an individual’s own metabolism.”

    So let’s take them off the market as well…or not…